No Maintenance, No Gain in Long-term Treatment of Eosinophilic Esophagitis
- PMID: 30678839
- PMCID: PMC8042781
- DOI: 10.1016/j.cgh.2018.07.038
No Maintenance, No Gain in Long-term Treatment of Eosinophilic Esophagitis
Conflict of interest statement
Conflicts of interest
The author discloses the following: Evan Dellon is a consultant for Adare, Allakos, Alivio, Banner, Calypso, Celgene/Receptos, Enumeral, EsoCap, GSK, Regeneron, Robarts, and Shire; has received research funding from Adare, Allakos Celgene/Receptos, Miraca, Meritage, Nutricia, Regeneron, and Shire; and has received educational grants from Banner and Holoclara.
Comment on
-
Maintenance Treatment Of Eosinophilic Esophagitis With Swallowed Topical Steroids Alters Disease Course Over A 5-Year Follow-up Period In Adult Patients.Clin Gastroenterol Hepatol. 2019 Feb;17(3):419-428.e6. doi: 10.1016/j.cgh.2018.05.045. Epub 2018 Jun 11. Clin Gastroenterol Hepatol. 2019. PMID: 29902648
References
-
- Straumann A, Spichtin HP, Grize L, et al. Natural history of primary eosinophilic esophagitis: a follow-up of 30 adult patients for up to 11.5 years. Gastroenterology 2003;125:1660–1669. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
